EZH2 in cancer progression and potential application in cancer therapy: A friend or foe?

Ke Sin Yan, Chia Yuan Lin, Tan Wei Liao, Cheng Ming Peng, Shou Chun Lee, Yi Jui Liu, Wing P. Chan, Ruey Hwang Chou

研究成果: 雜誌貢獻回顧型文獻

32 引文 斯高帕斯(Scopus)

摘要

Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes trimethylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors.
原文英語
文章編號1172
期刊International Journal of Molecular Sciences
18
發行號6
DOIs
出版狀態已發佈 - 六月 1 2017

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

指紋 深入研究「EZH2 in cancer progression and potential application in cancer therapy: A friend or foe?」主題。共同形成了獨特的指紋。

  • 引用此